G5移动连续血糖监测设备成本-效果数据集

数据集获取（Figshare）

• 源站标题：Cost-effectiveness of G5 Mobile continuous glucose monitoring device compared to self-monitoring of blood glucose alone for people with type 1 diabetes from the Canadian societal perspective
• DOI：10.6084/m9.figshare.5245534.v2
• 发布日期：2017-08-11
• 文件数：3 个
• 文件总体积：52.21 KB
• 源站页面：https://tandf.figshare.com/articles/dataset/Cost_Effectiveness_of_G5_Mobile_Continuous_Glucose_Monitoring_CGM_device_Compared_with_Self-Monitoring_of_Blood_Glucose_SMBG_alone_for_people_with_Type_1_diabetes_from_the_Canadian_societal_Perspective/5245534

命令行下载

curl -L -o "Supplemental material 2.docx" "https://ndownloader.figshare.com/files/8965705"
curl -L -o "Supplemental material 3.docx" "https://ndownloader.figshare.com/files/8965708"
curl -L -o "supplemental material 1.docx" "https://ndownloader.figshare.com/files/8965711"

文件清单

• Supplemental material 2.docx（20.00 KB）
• Supplemental material 3.docx（13.10 KB）
• supplemental material 1.docx（19.11 KB）

文件总体积 52.21 KB（源站 API 实测）。

数据加载示例（图像类）

from PIL import Image
import glob, os

files = (glob.glob(os.path.join(path, "**", "*.png"), recursive=True)
       + glob.glob(os.path.join(path, "**", "*.jpg"), recursive=True)
       + glob.glob(os.path.join(path, "**", "*.tif"), recursive=True))
print("图像文件数:", len(files))
img = Image.open(files[0]); print("尺寸/模式:", img.size, img.mode)

# torchvision Dataset 方式:
# from torchvision import datasets
# ds = datasets.ImageFolder(path)  # 要求 子目录=类别

目录组织与标注格式以源站说明和下载后实际文件为准。

数据说明

Aims: To evaluate the cost-effectiveness of real-time continuous glucose monitoring (CGM) compared to self-monitoring of blood glucose (SMBG) alone in people with type 1 diabetes (T1DM) using multiple daily injections (MDI) from the Canadian societal perspective.
Methods: The IMS CORE Diabetes Model (v.9.0) was used to assess the long-term (50 years) cost-effectiveness of real-time CGM (G5 Mobile CGM System; Dexcom, Inc., San Diego, CA) compared with SMBG alone for a cohort of adults with poorly-controlled T1DM. Treatment effects and baseline characteristics of patients were derived from the DIAMOND randomized controlled clinical trial; all other assumptions and costs were sourced from published research. The accuracy and clinical effectiveness of G5 Mobile CGM is the same as the G4 Platinum CGM used in the DIAMOND randomized clinical trial. Base case assumptions included (a) baseline HbA1c of 8.6%, (b) change in HbA1c of –1.0% for CGM users vs –0.4% for SMBG users, and © disutilities of –0.0142 for non-severe hypoglycemic events (NSHEs) and severe hypoglycemic events (SHEs) not requiring medical intervention, and –0.047 for SHEs requiring medical resources. Treatment costs and outcomes were discounted at 1.5% per year.
Results: The incremental cost-effectiveness ratio for the base case G5 Mobile CGM vs SMBG was $33,789 CAD/quality-adjusted life-year (QALY). Sensitivity analyses showed that base case results were most sensitive to changes in percentage reduction in hypoglycemic events and disutilities associated with hypoglycemic events. The base case results were minimally impacted by changes in baseline HbA1c level, incorporation of indirect costs, changes in the discount rate, and baseline utility of patients.
Conclusions: The results of this analysis demonstrate that G5 Mobile CGM is cost-effective within the population of adults with T1DM using MDI, assuming a Canadian willingness-to-pay threshold of $50,000 CAD per QALY.

许可

CC BY 4.0

引用

学术使用请引用 DOI 10.6084/m9.figshare.5245534.v2（source: https://tandf.figshare.com/articles/dataset/Cost_Effectiveness_of_G5_Mobile_Continuous_Glucose_Monitoring_CGM_device_Compared_with_Self-Monitoring_of_Blood_Glucose_SMBG_alone_for_people_with_Type_1_diabetes_from_the_Canadian_societal_Perspective/5245534）。